Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM
Table 5
Demographic and laboratory characteristics of DILI and non-DILI in HR cases.
DILI (n = 15)
Non-DILI (n = 255)
Statistics
value
Age, years
6.0 ± 3.6
7.1 ± 3.5
−0.997∆
0.319
Gender, n (%)
Male
6 (3.5)
165 (96.5)
3.724#
0.054
Female
9 (9.1)
90 (90.9)
Han ethnicity, n (%)
6 (40.0)
128 (50.2)
0.589#
0.443
BMI, kg/m2
16.7 ± 1.3
16.7 ± 1.9
−0.612∆
0.540
Prophylactic agents, n (%)
9 (60.0)
109 (42.7)
1.714#
0.190
Baseline renal function
Creatinine, mg/dl
0.30 ± 0.10
0.36 ± 0.13
−1.881∆
0.060
Cystatin C, mg/L
0.57 ± 0.14
0.60 ± 0.15
−0.250∆
0.803
Urea, mmol/L
3.88 ± 1.87
4.40 ± 1.66
−0.914∆
0.361
Uric acid, μmol/L
219.2 ± 64.3
256.5 ± 82.5
−1.349∆
0.177
Baseline liver function
Albumin, g/L
38.9 ± 5.3
42.3 ± 4.8
−2.335∆
0.020
Total bilirubin, μmol/L
5.46 ± 2.01
5.60 ± 3.11
−0.502∆
0.616
ALT, U/L
42.8 ± 22.3
39.1 ± 30.6
−1.459∆
0.145
GGT, U/L
48.3 ± 26.0
39.8 ± 46.4
−2.332∆
0.020
AST, U/L
46.1 ± 10.4
37.1 ± 21.3
−3.580
＜0.001
ALP, U/L
190.4 ± 37.6
176.5 ± 55.9
−1.491∆
0.136
Baseline blood routine
White blood cell count, ×109/L
5.79 ± 3.42
5.04 ± 3.22
−1.113∆
0.266
Red blood cell count, ×1012/L
3.52 ± 0.42
3.59 ± 0.61
−0.393∆
0.694
Platelet count, ×109/L
281.6 ± 113.4
301.1 ± 122.3
−0.689∆
0.491
Hemoglobin, g/L
94.7 ± 11.3
99.5 ± 12.9
−1.381∆
0.167
∆ Z value, statistics of the Mann–Whitney U test; #χ2 value, statistics of the chi-square test. DILI, drug-induced liver injury; HR, high risk; HD-MTX, high-dose methotrexate; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; ALP, alkaline phosphatase.
